Early Outpatient Treatment for Covid-19 with Convalescent Plasma | NEJM
Original Article from The New England Journal of Medicine — Early Outpatient Treatment for Covid-19 with Convalescent Plasma
Related Articles
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes
AbstractPrognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies. We retrospectively analyzed medical records of 43 patients with…
MOLECULAR GENETIC TESTING PATTERNS FOR PATIENTS WITH NEWLY… by Daniel Pollyea
EHA Library; Pollyea D. May 18 2017; 180699;
Abstract 6259: Molecular biomarker testing and targeted therapy patterns in patients with acute myelogenous leukemia (AML): A real-world data analysis
Abstract. Background and Objective: Molecular testing and targeted treatments for patients (pts) diagnosed with AML have evolved in recent years. Real-world testing patterns, including next-generation…
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma
PURPOSE Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk of…
Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies
Purpose: This study sought to describe the changes in immune response to a third dose of either Pfizer’s or Moderna’s COVID-19 mRNA vaccine (3V) among…
Characteristics of patients with hematologic malignancies without seroconversion post-COVID19 third vaccine dosing (3V): Real-world data from large midwestern healthcare system.
e19513 Background: Patients (Pts) with hematologic malignancies (HM) are at greater risk of severe morbidity and mortality caused by COVID19 and show a lower response…
Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
Patients treated recently for a B-lymphoid malignancy are shown to have particularly high risks of severe COVID-19 compared to multiple control cohorts of patients with…
COVID‐19 vaccine effectiveness in patients with hematologic malignancy
Click on the article title to read more.
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of…
COVID-19 and Cancer—A Review of the Registry-Based Pandemic Response
This review describes the registry efforts made during the COVID-19 pandemic with the aim of investigating and sharing information about the history, risk factors, and…